case_images: PMC10757231_01
case_images: Dermatomyositis of (A) the face and (B) upper portion of the back at presentation.
case_images: gr1.jpg
case_images: PMC10757231_01_gr1.jpg
case_images: fig1
case_images: On examination, there were violaceous patches and plaques typical of DM: on the face, including a heliotrope discoloration of the eyelids; on the fingers, with Gottron papules; and characteristic lesions on the chest, back, lateral aspect of the hips and thighs (Fig 1, A and B).
case_images: (A) Face and (B) upper portion of the back after 5 cycles of intravenous immunoglobulin, and before anifrolumab administration.
case_images: gr2.jpg
case_images: PMC10757231_01_gr2.jpg
case_images: fig2
case_images: Improvement of (A) the face and (B) back following 1 dose of anifrolumab.
case_images: gr3.jpg
case_images: PMC10757231_01_gr3.jpg
case_images: fig3
case_images: Anifrolumab administration resulted in marked skin improvement of the torso that was apparent after the first injection (Fig 3, A and B), and was continued for an additional 3 doses, leading to near-clearing of the facial activity. At that time, progressive metastatic hepatic, osseous, and lymph node disease was identified, chemotherapy was then reinstituted, and the decision was made to pause treatment with anifrolumab.
case_images: Resolution of (A) facial and (B) back activity following 4 doses of anifrolumab.
case_images: gr4.jpg
case_images: PMC10757231_01_gr4.jpg
case_images: fig4
case_images: Skin disease remained under excellent control for 2 months after the last anifrolumab injection (Fig 4, A and B), at which point the face, scalp, neck, and chest flared, prompting plans to resume the anifrolumab.